Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.51 |
| ▸ | PPARA | Q07869 | 5/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5124569 | 0.94 | LMNA (0.51) | PPARGPPARALMNATP53POLB | |
| SCHEMBL4885359 | 0.89 | PPARA (0.52) | PPARGPPARALMNATP53SMN1; SMN2 | |
| SCHEMBL504044 | 0.88 | PPARG (0.54) | PPARGPPARALMNATP53PPARD | |
| SCHEMBL4889426 | 0.87 | PPARA (0.54) | PPARGPPARALMNATP53POLB | |
| SCHEMBL4893815 | 0.86 | PPARA (0.50) | PPARGPPARALMNATP53POLB | |
| SCHEMBL4889024 | 0.85 | PPARA (0.52) | PPARGPPARALMNAPPARDMAPT | |
| SCHEMBL3582601 | 0.85 | PPARA (0.53) | PPARGPPARALMNATP53POLB | |
| SCHEMBL3578702 | 0.84 | PPARG (0.55) | PPARGPPARATP53POLBTARBP2 | |
| SCHEMBL4893334 | 0.84 | TP53 (0.52) | PPARGPPARALMNATP53POLB | |
| SCHEMBL4897132 | 0.83 | MAPT (0.46) | PPARGPPARALMNATP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207685-A1 | Heterocyclic Compounds As Modulators Of Peroxisome Proliferator Activated Receptors, Useful For The Treatment And/Or Prevention Of Disorders Modulated By A Ppar | ELI LILLY AND COMPANY (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080207685-A1 | Heterocyclic Compounds As Modulators Of Peroxisome Proliferator Activated Receptors, Useful For The Treatment And/Or Prevention Of Disorders Modulated By A Ppar | ELI LILLY AND COMPANY (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080207685-A1 | Heterocyclic Compounds As Modulators Of Peroxisome Proliferator Activated Receptors, Useful For The Treatment And/Or Prevention Of Disorders Modulated By A Ppar | ELI LILLY AND COMPANY (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080167310-A1 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR) | GOSSETT LYNN STACY | 2008-07-10 | — | — | US | disclosed |
| US-20080167310-A1 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR) | GOSSETT LYNN STACY | 2008-07-10 | — | — | US | disclosed |
| US-20080167310-A1 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR) | GOSSETT LYNN STACY | 2008-07-10 | — | — | US | disclosed |
| US-20080146631-A1 | OXAZOLYL-ARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | BROOKS DAWN ALISA | 2008-06-19 | — | — | US | disclosed |
| US-7351728-B2 | Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists | ELI LILLY AND COMPANY (US) | 2008-04-01 | — | — | US | disclosed |
| US-7282501-B2 | Modulators of peroxisome proliferator activated receptors (PPAR) | ELI LILLY AND COMPANY (US) | 2007-10-16 | — | — | US | disclosed |
| US-7282501-B2 | Modulators of peroxisome proliferator activated receptors (PPAR) | ELI LILLY AND COMPANY (US) | 2007-10-16 | — | — | US | disclosed |
| EP-1206457-B1 | BIARYL-OXA(THIA)ZOLE DERIVATIVES AND THEIR USE AS PPARS MODULATORS | LILLY CO ELI (US) | 2003-10-15 | — | — | EP | disclosed |
| US-6610696-B2 | Such as 2-(4-(2-(2-(4-(3,5-dimethyl-isoxazol-4-yl)-phenyl)-5-methyloxazol-4-yl) -ethyoxy)-phenoxy)-2-methylpropionic acid for treatment of diabetes (lowering serum triglycerides) | ELI LILLY AND COMPANY | 2003-08-26 | — | — | US | disclosed |
| EP-1313715-A1 | OXAZOLYL-ARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | ELI LILLY AND COMPANY (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20030045558-A1 | Modulators of peroxisome proliferator activated receptors | ELI LILLY & COMPANY LILY CORPORATE CENTER (US) | 2003-03-06 | — | — | US | disclosed |
| WO-2002100403-A1 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR) | ELI LILLY AND COMPANY (US) | 2002-12-19 | — | — | WO | disclosed |
| WO-2001016120-A9 | BIARYL-OXA(THIA)ZOLE DERIVATIVES AND THEIR USE AS PPARS MODULATORS | LILLY CO ELI (US) | 2002-07-11 | — | — | WO | disclosed |
| US-6417212-B1 | PHENYLOXAZOLE SUBSTITUTED ON BENZENEOXYPROPIONIC ACID OR ESTERS | ELI LILLY & COMPANY | 2002-07-09 | — | — | US | disclosed |
| EP-1206457-A1 | BIARYL-OXA(THIA)ZOLE DERIVATIVES AND THEIR USE AS PPARS MODULATORS | ELI LILLY AND COMPANY (US) | 2002-05-22 | — | — | EP | disclosed |
| WO-2002018355-A1 | OXAZOLYL-ARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-03-07 | — | — | WO | disclosed |
| WO-2001016120-A1 | BIARYL-OXA(THIA)ZOLE DERIVATIVES AND THEIR USE AS PPARS MODULATORS | ELI LILLY AND COMPANY (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167310-A1 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR) | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885LMNA 2660/4885 |
| US-20080146631-A1 | OXAZOLYL-ARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | PPARA, PPARG, PPARD | PPARG 2/4885PPARA 1/4885LMNA 1860/4885 |
| US-20080207685-A1 | Heterocyclic Compounds As Modulators Of Peroxisome Proliferator Activated Receptors, Useful For The Treatment And/Or Prevention Of Disorders Modulated By A Ppar | PPARG, PPARD, PPARA | PPARG 1/4885PPARA 3/4885LMNA 1948/4885 |
| US-20030045558-A1 | Modulators of peroxisome proliferator activated receptors | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885LMNA 1897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.